We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.
Solid Tumors with RET Abnormalities
Cancer Supportive Care
Fosnetupitant - Palonosetron
Fosnetupitant - Palonosetron IV
IV - China - CINV2,3
Global - Cancer Anorexia-Cachexia in NSCLC5 patients
Ghrelin Receptor Antagonist - Prader-Willi Syndrome - Open for partnering
Ghrelin Receptor Agonist - Partnered
The safety and efficacy of the agents identified for the investigational uses have not been established: these agents have not been approved for commercial use by any regulatory authority worldwide, except where noted. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.
1.Vepafestinib is co-developed by Helsinn Healthcare SA and Taiho Pharmaceutical Co. Ltd.
2.Chemotherapy-Induced Nausea and Vomiting
3.Approved in multiple territories, including USA and EU
4.Approved in Japan
5.Non-Small Cell Lung Cancer